AIM ImmunoTech Inc. (AIM)
| Market Cap | 7.19M |
| Revenue (ttm) | 146,000 |
| Net Income (ttm) | -15.21M |
| Shares Out | 764.19K |
| EPS (ttm) | -24.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,651 |
| Open | 8.95 |
| Previous Close | 9.15 |
| Day's Range | 8.79 - 9.39 |
| 52-Week Range | 8.00 - 14.93 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 2.75 (-68.71%) |
| Earnings Date | Aug 13, 2025 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also d... [Read more]
Financial Performance
In 2024, AIM ImmunoTech's revenue was $170,000, a decrease of -15.84% compared to the previous year's $202,000. Losses were -$17.32 million, -40.20% less than in 2023.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AIM stock is "Strong Buy." The 12-month stock price target is $2.75, which is a decrease of -68.71% from the latest price.
News
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM's drug A...
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025
AIM ImmunoTech Resumes Trading on NYSE American
Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th Company trading under the ticker “AIM” NYSE American effective at the start of trading ...
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its ...
Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript
Aimia Inc. (OTCPK:AIMFF) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Rhys Summerton - Executive Chairman Steven L...
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM's...
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to trea...
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to t...
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference...
Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript
Aimia Inc. (OTCPK:AIMFF) Q4 2024 Results Conference Call March 28, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Rhys Summert...
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that th...
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company's Board of Directors (the “Board”) has, by unanimous v...
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2 Several subjects who received the highest dose in Phase 1 will also be included in Phase 2
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) ...
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration ...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune ...
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Ef...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (t...